{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:43:42Z","timestamp":1777859022899,"version":"3.51.4"},"reference-count":69,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Prim Care Community Health"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>Prostate-specific antigen (PSA) screening has played a critical role in reducing prostate cancer mortality but remains controversial due to concerns regarding overdiagnosis, overtreatment, and inconsistent screening guidelines. In 2012, the United States Preventive Services Task Force (USPSTF) issued a grade D recommendation against PSA screening, leading to a national decline in PSA testing and prostate biopsy rates. This was followed by an increase in the incidence of metastatic prostate cancer at diagnosis. The USPSTF has since revised its recommendation to grade C, emphasizing shared decision-making for men aged 55 to 69\u2009years. However, variability in screening recommendations across professional societies has resulted in clinical uncertainty, particularly for primary care physicians (PCPs), who frequently initiate PSA testing and urology referrals. This review provides an evidence-based overview of PSA screening tailored for the PCP. We performed a comprehensive literature review using Ovid MEDLINE, PubMed, Embase, and the Cochrane Library, including systematic reviews published between January 2020 and April 2025, and current guidelines from the American Urological Association (AUA), National Comprehensive Cancer Network (NCCN), European Association of Urology (EAU), and American Cancer Society (ACS). We summarize the evolving landscape of PSA screening and its integration with contemporary tools such as shared decision-making, multiparametric magnetic resonance imaging (mpMRI), and transperineally targeted biopsy. We advocate for initiating PSA screening between the ages of 45 and 49 in men with average or elevated risk, based on long-term evidence demonstrating the value of an early baseline PSA level and risk-stratified follow-up. This approach, coupled with improved diagnostic tools, can help PCPs navigate guideline variability and implement a rational, common-sense strategy to maximize early detection while minimizing harm.<\/jats:p>","DOI":"10.1177\/21501319251401393","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T12:22:06Z","timestamp":1766492526000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["An Evidenced Based Review and Common-Sense Approach to Prostate Cancer Screening for Primary Care Physicians, in an Era of Conflicting Guideline Recommendations and Debate"],"prefix":"10.1177","volume":"16","author":[{"given":"Mahnoor","family":"Ashraf","sequence":"first","affiliation":[{"name":"Mayo Clinic, Phoenix, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mouneeb","family":"Choudry","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Phoenix, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Frendl","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Phoenix, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6903-4610","authenticated-orcid":false,"given":"Gregory M.","family":"Garrison","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Stephenson","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4646-1748","authenticated-orcid":false,"given":"Nathaniel","family":"Miller","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack R.","family":"Andrews","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Phoenix, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"e_1_3_2_2_2","unstructured":"American Cancer Society. Key statistics for prostate cancer. Published 2025. Accessed April 16 2025."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-007-9083-8"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27594"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-3-200808050-00008"},{"issue":"19","key":"e_1_3_2_6_2","first-page":"3696","article-title":"Declines in prostate cancer incidence and mortality: the possible role of screening","volume":"123","author":"Jemal A","year":"2017","unstructured":"Jemal A, Fedewa SA, Ma J, Siegel R, Lin CC, Brawley O, et al. Declines in prostate cancer incidence and mortality: the possible role of screening. Cancer. 2017;123(19):3696-3703.","journal-title":"Cancer"},{"issue":"6","key":"e_1_3_2_7_2","first-page":"858","article-title":"Association of the 2012 USPSTF prostate cancer screening recommendation with stage and grade migration","volume":"114","author":"Desai NR","year":"2022","unstructured":"Desai NR, Holt SK, Etzioni R, Gore JL, Lin DW, Wright JL, et al. Association of the 2012 USPSTF prostate cancer screening recommendation with stage and grade migration. JNCI. 2022;114(6):858-866.","journal-title":"JNCI"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13793"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.2246"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3710"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003491"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0019"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.03.027"},{"key":"e_1_3_2_14_2","unstructured":"American Cancer Society. ACS recommendations for prostate cancer early detection. Published 2025. Accessed April 16 2025."},{"key":"e_1_3_2_15_2","volume-title":"Prostate Specific Antigen","author":"David MK","year":"2022","unstructured":"David MK, Leslie SW. Prostate Specific Antigen. StatPearls. 2022."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11481.x"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2022.107395"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8145173"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2022.08.003"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajur.2014.09.008"},{"issue":"2","key":"e_1_3_2_21_2","first-page":"175","article-title":"Quantifying PSA\u2019s role in stage migration and mortality trends","volume":"19","author":"Etzioni R","year":"2008","unstructured":"Etzioni R, Gulati R, Tsodikov A, Weiss NS, Cha R, Cooperberg MR, et al. Quantifying PSA\u2019s role in stage migration and mortality trends. Cancer Causes Control. 2008;19(2):175-181.","journal-title":"Cancer Causes Control"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27594"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1089\/dna.1987.6.429"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj307"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-12-26"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.1704"},{"issue":"17","key":"e_1_3_2_27_2","first-page":"1248","article-title":"Suicide and accidental deaths after prostate cancer diagnosis","volume":"102","author":"Fang F","year":"2010","unstructured":"Fang F, Keating NL, Mucci LA, Stampfer MJ, Valdimarsd\u00f3ttir U, Johansson JE, et al. Suicide and accidental deaths after prostate cancer diagnosis. J Natl Cancer Inst. 2010;102(17):1248-1251.","journal-title":"J Natl Cancer Inst"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.10.021"},{"issue":"3","key":"e_1_3_2_29_2","first-page":"301","article-title":"Digital rectal examination for prostate cancer screening: value and limitations","volume":"74","author":"Loeb S","year":"2018","unstructured":"Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam RK, et al. Digital rectal examination for prostate cancer screening: value and limitations. Eur Urol. 2018;74(3):301-302.","journal-title":"Eur Urol"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810084"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.02.009"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0969"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114635"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810696"},{"key":"e_1_3_2_35_2","article-title":"Long-term prediction of lethal prostate cancer using PSA in midlife","volume":"341","author":"Lilja H","year":"2010","unstructured":"Lilja H, Cronin AM, Dahlin A, Manjer J, Nilsson PM, Eastham JA, et al. Long-term prediction of lethal prostate cancer using PSA in midlife. BMJ. 2010;341:c4521.","journal-title":"BMJ"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.01.009"},{"key":"e_1_3_2_37_2","volume-title":"SEER Cancer Statistics Review, 1975-2017, National Cancer Institute","author":"Howlader N","unstructured":"Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2017, National Cancer Institute. Bethesda, MD, https:\/\/seer.cancer.gov\/csr\/1975_2017\/, based on November 2019 SEER data submission, posted to the SEER web site, April 2020."},{"issue":"1","key":"e_1_3_2_38_2","article-title":"Association of baseline PSA with long-term diagnosis of significant prostate cancer: secondary analysis of PLCO","volume":"3","author":"Kovac E","year":"2020","unstructured":"Kovac E, Crawford ED, Grubb RL, Andriole GL, Thompson IM, Tangen CM, et al. Association of baseline PSA with long-term diagnosis of significant prostate cancer: secondary analysis of PLCO. JAMA Netw Open. 2020;3(1):e1919284.","journal-title":"JAMA Netw Open"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.02.033"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/465816"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32401-1"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801993"},{"key":"e_1_3_2_43_2","first-page":"3816","article-title":"Recommendations for mpMRI image quality and interpretation","volume":"48","author":"Padhani AR","year":"2023","unstructured":"Padhani AR, Haider MA, Villers A, Turkbey B, Rosenkrantz AB, Barentsz JO. Recommendations for mpMRI image quality and interpretation. Abdom Radiol. 2023;48:3816-3829.","journal-title":"Abdom Radiol"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001414"},{"issue":"6","key":"e_1_3_2_45_2","first-page":"1613","article-title":"Infectious complications following prostate biopsy: time to rethink prophylaxis?","volume":"196","author":"Loeb S","year":"2016","unstructured":"Loeb S, Vellekoop A, Carter HB, et al. Infectious complications following prostate biopsy: time to rethink prophylaxis? J Urol. 2016;196(6):1613-1614.","journal-title":"J Urol"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00100-7"},{"issue":"1","key":"e_1_3_2_47_2","first-page":"55","article-title":"Transperineal vs transrectal prostate biopsy: results from the randomized ProBE-PC trial","volume":"212","author":"Mian BM","year":"2024","unstructured":"Mian BM, Carter HB, Ward JF, Taneja SS, Bjurlin M, Carter A, et al. Transperineal vs transrectal prostate biopsy: results from the randomized ProBE-PC trial. J Urol. 2024;212(1):55-62.","journal-title":"J Urol"},{"key":"e_1_3_2_48_2","first-page":"112","article-title":"Sepsis risk in transperineal prostate biopsy without antibiotics: systematic review","volume":"21","author":"Grummet JP","year":"2024","unstructured":"Grummet JP, Gorin MA, Patel MI, Hsieh AC, Lughezzani G, Benfante N, et al. Sepsis risk in transperineal prostate biopsy without antibiotics: systematic review. Nat Rev Urol. 2024;21:112-120.","journal-title":"Nat Rev Urol"},{"issue":"2","key":"e_1_3_2_49_2","first-page":"205","article-title":"PREVENT trial: infection risk after transperineal vs transrectal biopsy","volume":"10","author":"Tewari A","year":"2024","unstructured":"Tewari A, Sooriakumaran P, Sivaraman A, Srivastava A, Grover S, Berglund R, et al. PREVENT trial: infection risk after transperineal vs transrectal biopsy. JAMA Oncol. 2024;10(2):205-212.","journal-title":"JAMA Oncol"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0000000000000320"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.11.005"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214122"},{"issue":"8","key":"e_1_3_2_53_2","first-page":"701","article-title":"Patient-reported outcomes after monitoring, surgery, or radiotherapy in the ProtecT trial","volume":"42","author":"Donovan JL","year":"2024","unstructured":"Donovan JL, Hamdy FC, Lane JA, Metcalfe C, Holding P, Davis M, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy in the ProtecT trial. J Clin Oncol. 2024;42(8):701-712.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113162"},{"issue":"1","key":"e_1_3_2_55_2","first-page":"83","article-title":"Active surveillance versus watchful waiting for prostate cancer: review and contemporary practice","volume":"1","author":"Dall\u2019Era MA","year":"2015","unstructured":"Dall\u2019Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, et al. Active surveillance versus watchful waiting for prostate cancer: review and contemporary practice. JAMA Oncol. 2015;1(1):83-89.","journal-title":"JAMA Oncol"},{"issue":"2","key":"e_1_3_2_56_2","first-page":"310","article-title":"Anatomical radical prostatectomy: comparison of open and robotic outcomes","volume":"65","author":"Tewari A","year":"2014","unstructured":"Tewari A, Peabody J, Sarle R, Balakrishnan G, Hemal A, Menon M. Anatomical radical prostatectomy: comparison of open and robotic outcomes. Eur Urol. 2014;65(2):310-322.","journal-title":"Eur Urol"},{"issue":"10","key":"e_1_3_2_57_2","first-page":"1431","article-title":"Timing of salvage radiation therapy for prostate cancer recurrence after prostatectomy","volume":"6","author":"King CR","year":"2020","unstructured":"King CR, Kapp DS, Terris MK, et al. Timing of salvage radiation therapy for prostate cancer recurrence after prostatectomy. JAMA Oncol. 2020;6(10):1431-1439.","journal-title":"JAMA Oncol"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1807801"},{"issue":"4","key":"e_1_3_2_59_2","first-page":"500","article-title":"Three-year outcomes after hypofractionated vs conventional radiotherapy for prostate cancer","volume":"6","author":"Elliott SP","year":"2020","unstructured":"Elliott SP, Wilt TJ, Roberts K, et al. Three-year outcomes after hypofractionated vs conventional radiotherapy for prostate cancer. JAMA Oncol. 2020;6(4):500-509.","journal-title":"JAMA Oncol"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70040-3"},{"issue":"11","key":"e_1_3_2_61_2","first-page":"1126","article-title":"Patient-reported quality of life after primary treatment for localized prostate cancer (CEASAR study)","volume":"317","author":"Chen RC","year":"2017","unstructured":"Chen RC, Basak R, Meyer AM, et al. Patient-reported quality of life after primary treatment for localized prostate cancer (CEASAR study). JAMA. 2017;317(11):1126-1140.","journal-title":"JAMA"},{"issue":"3","key":"e_1_3_2_62_2","first-page":"267","article-title":"Adjuvant radiotherapy plus androgen deprivation for localized prostate cancer","volume":"13","author":"Mason MD","year":"2012","unstructured":"Mason MD, Parulekar WR, Sydes MR, et al. Adjuvant radiotherapy plus androgen deprivation for localized prostate cancer. Lancet Oncol. 2012;13(3):267-276.","journal-title":"Lancet Oncol"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.08.044"},{"key":"e_1_3_2_64_2","first-page":"191","article-title":"Targeted interventions for focal therapy of prostate cancer","volume":"16","author":"Bass EJ","year":"2019","unstructured":"Bass EJ, Pantelidou M, Salvador J, Winkler M, Kastner C, Winkler M, et al. Targeted interventions for focal therapy of prostate cancer. Nat Rev Urol. 2019;16:191-208.","journal-title":"Nat Rev Urol"},{"issue":"3","key":"e_1_3_2_65_2","first-page":"313","article-title":"Focal therapy for localized prostate cancer: what is needed to move from experimental to standard of care?","volume":"30","author":"van Son MJ","year":"2020","unstructured":"van Son MJ, de Bruijn R, Noordman BJ, Hendriks RJ, Barentsz JO, F\u00fctterer JJ, et al. Focal therapy for localized prostate cancer: what is needed to move from experimental to standard of care? Curr Opin Urol. 2020;30(3):313-320.","journal-title":"Curr Opin Urol"},{"issue":"3","key":"e_1_3_2_66_2","first-page":"313","article-title":"Focal therapy: where are we now?","volume":"30","author":"Donaldson IA","year":"2020","unstructured":"Donaldson IA, Alonzi R, Barratt D, et al. Focal therapy: where are we now? Curr Opin Urol. 2020;30(3):313-320.","journal-title":"Curr Opin Urol"},{"issue":"2","key":"e_1_3_2_67_2","first-page":"153","article-title":"How good is multiparametric MRI in predicting Gleason score?","volume":"20","author":"Moldovan PC","year":"2017","unstructured":"Moldovan PC, Van den Broeck T, Sylvester R, et al. How good is multiparametric MRI in predicting Gleason score? Prostate Cancer Prostatic Dis. 2017;20(2):153-163.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)36517-5"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-023-04002-z"},{"key":"e_1_3_2_70_2","unstructured":"National Comprehensive Cancer Network. Prostate cancer early detection. Version 3. 2024. Accessed 2025."}],"container-title":["Journal of Primary Care &amp; Community Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/21501319251401393","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/21501319251401393","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/21501319251401393","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:23:43Z","timestamp":1777508623000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/21501319251401393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":69,"alternative-id":["10.1177\/21501319251401393"],"URL":"https:\/\/doi.org\/10.1177\/21501319251401393","relation":{},"ISSN":["2150-1319","2150-1327"],"issn-type":[{"value":"2150-1319","type":"print"},{"value":"2150-1327","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"article-number":"21501319251401393"}}